TTD | Drug: D0N3QF

Drug General Information
Drug ID	D0N3QF
Former ID	DIB001802
Drug Name	AZD-5122
Indication	Chronic obstructive pulmonary disease [ICD9: 490-492, 494-496; ICD10:J40-J44, J47]		Phase 1	[522796]
Company	AstraZeneca plc
Target and Pathway
Target(s)	High affinity interleukin-8 receptor B	Target Info	Modulator	[551119]
KEGG Pathway	Cytokine-cytokine receptor interaction
	Chemokine signaling pathway
	Endocytosis
	Epithelial cell signaling in Helicobacter pylori infection
NetPath Pathway	TNFalpha Signaling Pathway
PANTHER Pathway	Inflammation mediated by chemokine and cytokine signaling pathway
PANTHER Pathway	Interleukin signaling pathway
Pathway Interaction Database	IL8- and CXCR2-mediated signaling events
Reactome	Chemokine receptors bind chemokines
Reactome	G alpha (i) signalling events
WikiPathways	GPCRs, Class A Rhodopsin-like
	Peptide GPCRs
	GPCR ligand binding
	GPCR downstream signaling
	GPCRs, Other
References
Ref 522796	ClinicalTrials.gov (NCT00984477) Study to Investigate the Activity of AZD5122 When Given as a Single Dose to Healthy Male Subjects. U.S. National Institutes of Health.
Ref 551119	Molecular Approaches To Target GPCRs in Cancer Therapy. Pharmaceuticals 2011, 4(4), 567-589.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.

Drug Information